Ethicon — part of Johnson & Johnson (NYSE:JNJ) — announced today that it launched the Enseal X1 curved jaw tissue sealer.
Cincinnati-based Ethicon developed the Enseal as a new advanced bipolar energy device designed to increase procedural efficiency and provide stronger sealing and better access to more tissue than Medtronic’s LigaSure Maryland, according to a news release.
Indications for the device include colorectal, gynecological, bariatric surgery and thoracic procedures. It includes separate seal and cut capabilities, a 360-degree continuous shaft rotation that enables easy access to targeted tissue. Ethicon’s adaptive tissue technology allows the device to continuously sense changes in the condition of tissue and respond accordingly with the optimal amount of energy to minimize lateral thermal spread.
Enseal X1 curved jaw marks the first of a series of new advanced laparoscopic bipolar devices set to launch from Ethicon over the coming months as the company looks to expand its energy portfolio.
“Ethicon is the only company with the expertise deep enough and the energy portfolio broad enough to offer tailored, proven and reliable product and service solutions that span virtually every energy modality, surgical specialty and procedure,” Ethicon president Kate Masschelein said in the release. “We will continue to develop innovative solutions that leverage our decades of experience in surgery and our deep understanding of the science of tissue management, device-tissue interaction and OR safety to set new standards of performance in surgery.”